Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
NCT02866370
Unknown
The trial will recruit up to 120 patients; 90 with ovarian clear cell carcinoma and up to 30 with endometrial clear cell carcinoma. Patients will be randomised between chemotherapy and Nintedanib 200mg twice daily oral administration (PO) continuously. The primary diagnosis must be histologically confirmed and central pathological review of the presenting tumour or biopsy of relapsed disease must find at least 50% clear cell carcinoma with no serous differentiation
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/10/2016
Locations: Beatson West of Scotland Cancer Centre, Glasgow, Lanarkshire +16 locations
Conditions: Ovarian Clear Cell Carcinoma, Endometrial Clear Cell Carcinoma
Register for Updates
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama +132 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
NCT02423239
Unknown
This study is a trial of dexanabinol in patients with advanced tumours. The purposes of the protocol are to study different doses of the study drug to determine the maximum safe dose of the drug given in combination with standard chemotherapies and to further understand the safety of the study drug and to measure any reduction in size of patients' cancer tumour(s). Dexanabinol is a synthetic cannabinoid which has previously undergone clinical trials for traumatic brain injury (TBI) and in subje... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2016
Locations: University Hospital Bonn, Study Center Bonn (SZB) Clinical Study Core Unit Institute of Clinical Chemistry and Clinical Pharmacology University Hospital Bonn, Sigmund-Freud-Str. 25, Bonn, Not set +12 locations
Conditions: Hepatocellular Carcinoma, Pancreatic Cancer
Register for Updates
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
NCT00809133
Completed
The main purpose of this study is to assess the optimum dose of the following medications when they are given together: * BIBW 2992 and paclitaxel (Taxol) * BIBW 2992 and paclitaxel and bevacizumab (Avastin) * BIBW 2992 and carboplatin * BIBW 2992 and paclitaxel and carboplatin The effect of the different drug combinations will also be assessed.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2016
Locations: 1200.12.4402 Boehringer Ingelheim Investigational Site, London, Not set +1 locations
Conditions: Neoplasms
Register for Updates
A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
NCT00370552
Completed
The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2016
Locations: East Valley Hematology And Oncology Medical Group, Burbank, California +24 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
NCT00455533
Completed
The study will evaluate the effectiveness of ixabepilone when given after doxorubicin plus cyclophosphamide (AC) compared to standard treatment of paclitaxel given after doxorubicin plus cyclophosphamide in patients with early stage breast cancer. In addition the study will verify predefined biomarkers as well as discover new biomarkers that could identify patients who are more likely to respond to ixabepilone than standard paclitaxel based therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/25/2016
Locations: Comprehensive Cancer Center, Palm Springs, California +49 locations
Conditions: Breast Cancer
Register for Updates
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
NCT00900627
Completed
The main purpose of this study is to determine if AZD8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer. This study will be conducted in 2 parts: the first part (phase I) will determine a dose of AZD8931 that can be safely administered with paclitaxel chemotherapy. The second part (phase II) will determine the efficacy and safety of AZD8931 in combination with paclitaxel chemotherapy in breast cancer.
Gender:
ALL
Ages:
Between 18 years and 150 years
Trial Updated:
01/15/2016
Locations: Research Site, Brussels (Jette), Not set +39 locations
Conditions: Neoplasms, Breast Neoplasms, Breast Cancer
Register for Updates
International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel
NCT02051868
Unknown
Anal cancer is a relatively uncommon disease and there is currently no standard chemotherapy treatment for patients with inoperable locally recurrent or metastatic disease. The aim of this phase II study is compare two well known and largely used chemotherapy regimens - Cisplatin plus 5-fluorouracil vs Carboplatin plus Paclitaxel. The result of this study will set a standard of care for this disease and provide useful information for future Phase III trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/03/2015
Locations: Laura Gagnon, Boston, Massachusetts +2 locations
Conditions: Squamous Cell Carcinoma of the Anus
Register for Updates
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
NCT00511459
Completed
This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment of subjects with Her2-negative metastatic or locally recurrent breast cancer. AMG 386 is a man-made medication that is designed to stop the development of blood vessels in cancer tissues. Cancer tissues rely on the development of new blood vessels, a process called ang... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/07/2015
Locations: Research Site, Litchfield Park, Arizona +76 locations
Conditions: Locally Recurrent and Metastatic Breast Cancer
Register for Updates
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
NCT00850577
Terminated
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2015
Locations: Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona +54 locations
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
NCT00421889
Completed
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum tolerated dose (MTD) expansion (phase II) in ovarian and bladder cancer patients The clinical trial is now in the MTD (phase II) portion of the study enrolling bladder cancer patients. Enrollment of ovarian patients is complete.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2015
Locations: Gynecologic Oncology Associates, Newport Beach, California +10 locations
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
Register for Updates
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer
NCT01196741
Completed
The purpose of this study is to investigate whether the addition of the Src inhibitor saracatinib (AZD0530) to weekly paclitaxel improves efficacy, compared with paclitaxel plus placebo, in patients with relapsed platinum-resistant ovarian cancer. The trial will also determine toxicity and ascertain whether the combination of paclitaxel plus saracatinib should proceed to a phase III trial.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/17/2015
Locations: Addenbrooke's Hospital, Cambridge, Cambridgeshire +11 locations
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Register for Updates